Press release
Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Spasticity Treatment Landscape @ Spasticity Pipeline Outlook [https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Spasticity Pipeline Report
* On 20 August 2025, Celgene conducted a study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity.
* On 03 August 2025, Ipsen announced a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
* DelveInsight's Spasticity pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Spasticity treatment.
* The leading Spasticity Companies such as Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc . and others.
* Promising Spasticity Pipeline Therapies such as IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Baclofen, CORETOX Registered , BOTOX Registered and others.
Stay informed about the cutting-edge advancements in Spasticity treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Spasticity Clinical Trials Assessment [https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Spasticity Emerging Drugs Profile
* MTR-601: Motric Bio
MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein - myosin 2 - in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function. MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy. Currently, the drug is in Phase II stage of its development for the treatment of Spasticity.
* IPN10200: Ipsen
IPN10200 is a longacting botulinum neurotoxin candidate developed by Ipsen for the treatment of upper limb spasticity. Engineered for extended duration of effect, it aims to provide sustained relief from muscle hyperactivity by inhibiting acetylcholine release at neuromuscular junctions. As a targeted neurotoxin therapy, IPN10200 is designed to reduce muscle tone more consistently over time, potentially reducing injection frequency and improving patient convenience. Its development reflects Ipsen's strategic focus on neuroscience and its commitment to advancing innovative therapeutic options in spasticity management. Currently, the drug is in Phase I/II stage of its development for the treatment of Spasticity.
The Spasticity Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
* Spasticity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.
Learn more about Spasticity Drugs opportunities in our groundbreaking Spasticity research and development projects @ Spasticity Unmet Needs [https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Spasticity Companies
Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc . and others.
Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
Spasticity Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay informed about how we're transforming the future of Musculoskeletal @ Spasticity Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Spasticity Pipeline Report
* Coverage- Global
* Spasticity Companies- Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc . and others.
* Spasticity Pipeline Therapies- IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Baclofen, CORETOX Registered , BOTOX Registered and others.
* Spasticity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Spasticity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Spasticity Pipeline on our website @ Spasticity Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Spasticity: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Spasticity- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* MTR-601: Motric Bio
* Early Stage Products (Phase I/II)
* IPN10200: Ipsen
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Spasticity Key Companies
* Spasticity Key Products
* Spasticity- Unmet Needs
* Spasticity- Market Drivers and Barriers
* Spasticity- Future Perspectives and Conclusion
* Spasticity Analyst Views
* Spasticity Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spasticity-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spasticity-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4155042 • Views: …
More Releases from ABNewswire
Health A Bot Names CoreAge Rx the Best GLP-1 Brand in 2026, Recognizing Its Phys …
Image: https://www.abnewswire.com/upload/2026/02/08b583392b9c9e6b5db989fca8d55a97.jpg
Health A Bot has officially named CoreAge Rx the Best GLP-1 Brand in 2026 [https://www.healthabot.com/top-5-glp-1-brand-in-the-world-coreage-rx-tops-the-chart/], recognizing the company's commitment to physician-guided care, individualized treatment plans, and access to GLP-1 medications. The designation reflects Health A Bot's comprehensive evaluation of GLP-1 providers serving individuals seeking medically supervised weight management solutions.
In its 2026 review cycle, Health A Bot assessed leading GLP-1 brands based on clinical oversight, medication quality, personalization of care,…
Custom Packaging Boxes With Logo: Branding Guide
Image: https://www.abnewswire.com/upload/2026/02/a85b0085c76a144c61cb76a8aed92b66.jpg
In today's market, your product should stand out. Great products are crucial. But presentation could make or damage first impressions. This is where custom packaging containers play an important position. Packaging that carries your brand is no longer an afterthought. It is a strategic tool for brand success.
Customers decide great inside seconds. Packaging is frequently the primary tangible interplay they've with your emblem. It shapes their expectations and feelings.…
Nutritionsly Recognizes CoreAge Rx as the World's Best GLP-1 Provider, Highlight …
Image: https://www.abnewswire.com/upload/2026/02/49a060b2c5ce8e5e3c8c09910a5507f2.jpg
Nutritionsly has named CoreAge Rx as the Best GLP-1 provider in the world [https://www.nutritionsly.com/complete-review-of-coreage-rx-and-what-makes-it-the-best-glp-1-brand-in-2026/], recognizing the company's transparent pricing structure, licensed healthcare oversight, and comprehensive telemedicine-based weight management program. The recognition highlights CoreAge Rx's continued expansion as a structured and accessible provider of GLP-1 medications delivered through a streamlined virtual care model.
CoreAge Rx [https://www.coreagerx.com/] provides access to GLP-1 medications including semaglutide and tirzepatide through a fully integrated telemedicine platform.…
The LegalTech Platform Lawyers Actually Open Every Morning - How Phenomenon Stud …
(By Iryna Huk - Project Manager Lead, Phenomenon Studio February 18, 2026 LegalTech Compliance SaaS Web App Design)
Key Takeaways
LegalTech platforms fail adoption not because lawyers distrust technology - but because the products look and behave like they were designed for someone else. ClauseGuard was built with a user research foundation that put practicing attorneys in every design decision from day one.
Choosing web and design services [https://phenomenonstudio.com/web-design-services] that understand institutional trust…
More Releases for Spasticity
Spasticity Market: Rapid Growth & Investment Outlook to 2032 - DelveInsight
The Spasticity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spasticity pipeline products will significantly revolutionize the Spasticity market dynamics.
DelveInsight's "Spasticity Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide.
Treatment approaches combine pharmacological agents, intrathecal therapies,…
Muscle Spasticity Market Emerging Trends and Growth Prospects 2034
Introduction
Muscle spasticity is a condition characterized by involuntary muscle stiffness, spasms, and increased tone, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, stroke, or traumatic brain and spinal cord injuries. It significantly impacts mobility and quality of life, making effective management essential. With the rising incidence of neurological diseases and advancements in physiotherapy, drug therapies, and medical devices, the global muscle spasticity market is witnessing steady expansion.
According…
Spasticity Drugs Market Segments, Growth and Trends by Forecast by 2031
The report is segmented By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), Route of Administration (Oral, Intramuscular, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Get Sample Copy -https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10831
Major Companies operating in the Spasticity Drugs Market are:
Ipsen Pharma
Allergan
Acorda Therapeutics,…
Spasticity Drugs Top Companies Regional and Data Analysis to 2031
The Spasticity Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits.
Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Spasticity Drugs Market are:
• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Beximco Pharmaceuticals Ltd.
• Johnson & Johnson Private Limited
• Zydus Cadila
Contact Us:
If you have any queries about this report or if…
Spasticity Treatment Market Expecting Huge Demand in Upcoming Years
The Global Spasticity Treatment Market size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $8.8 Billion by 2034. Download now
The latest study released on the Global Spasticity Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Spasticity Treatment market study covers significant research data and proofs to be a handy resource…
